Drug intelligence / Profile preview

AI-520

Development stage: Preclinical
Lead developer: Apeximmune Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AI-520 is an anti-TIGIT monoclonal antibody designed to block the suppressive activity of TIGIT. It binds to TIGIT with high affinity, aiming to enhance immune responses, particularly in the context of cancer treatment. Developed by Apeximmune Therapeutics, Inc., AI-520 is currently in the preclinical phase and targets neoplasms.

Other names: AI 520AI520AI-520

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on AI-520.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-520.

Explore the full profile